1. Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report
- Author
-
Yoshikazu Yasuda, Yoshinori Hosoya, Hirofumi Fujii, Misato Maeno, Naohiro Sata, Atsushi Miki, Alan Kawarai Lefor, Atsushi Shimizu, Daisuke Matsubara, Noriyuki Fukushima, and Yasunaru Sakuma
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Splenectomy ,Case Report ,030230 surgery ,Neuroendocrine tumors ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Pancreatic tumor ,Pancreatic neuroendocrine tumor ,Genetics ,medicine ,Humans ,Lung cancer ,Liver metastasis ,Spleen metastasis ,business.industry ,Splenic Neoplasms ,Radiofrequency ablation ,Middle Aged ,medicine.disease ,Prognosis ,Primary tumor ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Pancreas ,Ovarian cancer ,business ,Somatostatin - Abstract
Background Long-term term survival in patients with pancreatic neuroendocrine tumors has been reported, even in patients with metastatic disease. Metastases to the spleen are extremely rare, but have been reported from a number of primary malignancies, such as breast cancer, lung cancer, melanoma and ovarian cancer. This is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor. Case presentation The patient presented as a 53 years old white male with anemia and fatigue. Physical examination revealed a left upper quadrant fullness and computed tomography showed a 24 cm left upper quadrant mass with multiple liver metastases, splenomegaly and a 1 cm mass in the spleen. Resection of the primary pancreatic tumor (T4N0M1) was accompanied by gastrectomy, splenectomy and resection of adherent bowel. The spleen contained a metastatic lesion 1.0 cm in diameter, consistent with a primary neuroendocrine tumor of the pancreas. This operation was followed 8 months later, by delayed resection of liver metastases. The patient receives monthly administration of somatostatin long-acting analogue and has undergone several ablations of liver lesions with percutaneous radiofrequency ablation as well as a second liver resection. The patient is alive seven years after initial presentation, with no evidence of disease on imaging studies. Conclusions This is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor. The patient initially presented with synchronous multiple liver metastases and a single splenic metastasis. After resection of the primary tumor and spleen, the patient has undergone aggressive cytoreductive surgery/ablation of liver lesions and somatostatin therapy with resulting long-term survival.
- Published
- 2017